Clinical and Medical Management of Conditions Caused by MDMA or ‘Ecstasy’
Routledge eBooks October 10, 2018 DOI: 10.4324/9781315158082-15 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA |
| Key findings | Argues that the MDMA market has become increasingly complex, including products with very high MDMA doses and substances sold as MDMA that contain other drugs. The chapter reviews incidences, dangers, treatments, causes of death, prevention strategies, and clinical management of MDMA-related toxicity. |
Abstract
In Chapter 15 , ‘Clinical and medical management of conditions caused by MDMA or “Ecstasy”’, Andrew Parrott provides an overview of the evolution of the MDMA market over the years, which has become increasingly more complex and multifaceted with the introduction of products containing very high doses of MDMA or substances passed as MDMA but actually containing a series of different products. A detailed analysis of incidences, dangers, and available treatments has been provided as well as a review of causes of death and prevention strategies. Andrew Parrott will also discuss the clinical presentation of toxicity and clinical management strategies for clinicians.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |